Technical Analysis for EXAI - Exscientia Limited
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 4.90 | 0.82% | 0.04 |
EXAI closed up 0.82 percent on Friday, November 1, 2024, on 36 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
Earnings due: Nov 7
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | 0.00% | |
| MACD Bearish Centerline Cross | Bearish | 0.00% | |
| MACD Bearish Signal Line Cross | Bearish | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Fell Below 20 DMA | Bearish | 0.82% | |
| Fell Below 50 DMA | Bearish | 0.82% | |
| Bollinger Band Squeeze | Range Contraction | 0.82% | |
| BB Squeeze Started | Range Contraction | 0.82% |
| Alert | Time |
|---|---|
| Possible NR7 | about 23 hours ago |
| Possible Inside Day | about 23 hours ago |
| Rose Above 10 DMA | 1 day ago |
| 10 DMA Resistance | 1 day ago |
| Up 3% | 1 day ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/07/2024
Exscientia is an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Our pipeline demonstrates our ability to rapidly translate scientific concepts into precision-designed therapeutic candidates, with more than 25 projects advancing, including the first three AI-designed drug candidates to enter Phase 1 clinical trials.
Sector: Healthcare
Industry: Biotechnology
Keywords: Life Sciences Artificial Intelligence Health Sciences Clinical Trial Precision Medicine Clinical Pharmacology Systems Biology Evidence Based Medicine
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Life Sciences Artificial Intelligence Health Sciences Clinical Trial Precision Medicine Clinical Pharmacology Systems Biology Evidence Based Medicine
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 7.91 |
| 52 Week Low | 3.8 |
| Average Volume | 606,622 |
| 200-Day Moving Average | 5.33 |
| 50-Day Moving Average | 5.06 |
| 20-Day Moving Average | 4.97 |
| 10-Day Moving Average | 5.00 |
| Average True Range | 0.25 |
| RSI (14) | 47.37 |
| ADX | 16.86 |
| +DI | 22.60 |
| -DI | 19.83 |
| Chandelier Exit (Long, 3 ATRs) | 4.67 |
| Chandelier Exit (Short, 3 ATRs) | 5.25 |
| Upper Bollinger Bands | 5.35 |
| Lower Bollinger Band | 4.59 |
| Percent B (%b) | 0.41 |
| BandWidth | 15.13 |
| MACD Line | 0.00 |
| MACD Signal Line | 0.00 |
| MACD Histogram | -0.0011 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 5.11 | ||||
| Resistance 3 (R3) | 5.13 | 5.09 | 5.08 | ||
| Resistance 2 (R2) | 5.09 | 5.03 | 5.08 | 5.06 | |
| Resistance 1 (R1) | 4.99 | 5.00 | 4.97 | 4.97 | 5.05 |
| Pivot Point | 4.95 | 4.95 | 4.94 | 4.94 | 4.95 |
| Support 1 (S1) | 4.85 | 4.89 | 4.83 | 4.83 | 4.75 |
| Support 2 (S2) | 4.81 | 4.86 | 4.80 | 4.74 | |
| Support 3 (S3) | 4.71 | 4.81 | 4.73 | ||
| Support 4 (S4) | 4.69 |
